What is Avid Bioservices?
Avid Bioservices operates as a specialized contract development and manufacturing organization (CDMO) headquartered in the United States. The company provides a comprehensive suite of integrated services, ranging from early-stage cell line development to full-scale commercial production. By maintaining rigorous CGMP standards, Avid Bioservices supports the complex requirements of pharmaceutical innovators, focusing specifically on mammalian cell culture, analytical development, and formulation. Their market position is defined by an ability to facilitate seamless technology transfers, ensuring that client programs move efficiently from clinical trials to market-ready commercialization.
How much funding has Avid Bioservices raised?
Avid Bioservices has raised a total of $1.5M across 1 funding round:
Debt
$1.5M
Debt (2003): $1.5M, investors not publicly disclosed
Key Investors in Avid Bioservices
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Avid Bioservices?
With the recent influx of capital, Avid Bioservices is well-positioned to scale its operational footprint and address the growing demand for high-quality biologics manufacturing. The strategic focus will likely center on increasing capacity for mammalian cell culture and optimizing analytical development workflows to reduce time-to-market for client pipelines. As the pharmaceutical industry continues to prioritize outsourcing for complex biologics, Avid Bioservices is poised to capture additional market share by enhancing its technical capabilities and reinforcing its reputation as a reliable partner for clinical and commercial-scale production. Future growth will be driven by the integration of advanced manufacturing technologies and the expansion of its service portfolio to meet evolving regulatory and technical standards.
See full Avid Bioservices company page